CPIC

China Pacific Insurance (2601.HK) declined 2.49% to HK$30.56, pressured by broader market weakness and profit-taking following a 15.58% year-to-date loss from HK$36.20, now trading 24.47% below its 52-week high of HK$40.46. The stock touched HK$30.40 intraday lows and recovered slightly by close, with turnover of HK$454.3M. Fundamentals remain supportive: Q1 net profit surged to HK$11.38B (+10.41% YoY) and operating revenue grew 2.32% YoY to HK$78.61B; Q1 ROE reached 12.92%. Valuation is compressed with PE at just 4.81x and PB at 0.81x, backed by a HK$294B market cap. Analyst views diverge: HSBC maintains Buy with a HK$44 target, while JPM flags dividend sustainability as key and favors Ping An; public funds remain materially underweight Hong Kong insurers at 2.13% of allocation.

China Pacific Insurance (CPIC, 2601.HK) closed at HK$31.34 today, up 1.88%, representing early recovery after the year-to-date decline of 13.43% from the starting price of HK$36.2. The rally is driven by stabilizing fundamentals: first-quarter net profit surged 10.41% year-over-year to HK$11.38 billion; management signaled plans to increase equity allocation in China's capital markets to enhance shareholder returns; HSBC raised its price target to HK$44 and maintained a buy rating. Nevertheless, the stock remains 22.54% below its 52-week peak of HK$40.46 from early February, indicating recovery is still nascent. Valuations are extraordinarily cheap—P/E at just 4.94x, P/B at 0.83x—yet such deeply depressed multiples may signal market caution on growth prospects in the near term.

China Pacific Insurance closed near flat at HKD 30.04 today, as institutional bullish views were offset by regulatory headwinds in the insurance sector. The stock has declined 17.02% year-to-date and is down 25.76% from its February high of HKD 40.46. However, recent positive developments from analysts—HSBC raised its target price to HKD 44 and Morgan Stanley maintained a buy rating—suggest growing institutional confidence in the company's fundamentals. First-quarter net profit rose 10.41% year-over-year to HKD 11.384 billion, with revenue up 2.32%, indicating stable operations. The valuation remains exceptionally attractive: PE stands at merely 4.73x, PB at 0.8x, and dividend yield at 4.4%, well below sector averages. That said, tightening regulatory scrutiny in the insurance industry persists, and the stock remains below its 60-day moving average of HKD 30.79, which could limit near-term recovery momentum.

China Pacific Insurance gained 1.07% to HKD 30.08 today, following profit-taking after the morning session's intraday high of HKD 30.16. The rebound was underpinned by HSBC Research's upgraded target price of HKD 44 with Buy rating and the company's strategic move to increase equity allocation to China's capital markets. Fundamentally, Q1 2026 net profit surged 10.41% year-over-year to HKD 11.38 billion while revenue rose 2.32%. Valuation remains compelling at PE of just 4.74, PB of 0.80, and dividend yield of 4.39%—among the most attractive in the market. Price-wise, the stock has declined 16.91% year-to-date and stands 25.65% below its 52-week high of HKD 40.46. However, sector tailwinds are constrained: public fund allocation to Hong Kong-listed insurers is just 2.13%, suggesting limited near-term capital inflows into the space.

China Pacific Insurance closed down 1.58% to HK$29.76, with morning losses of 1.45% narrowing in afternoon session, as sector underallocation and profit-taking headwinds weighed on sentiment. CICC data showed Hong Kong insurers remain underweighted by public funds at 2.13%, down 0.75ppts, while JPM's emphasis on dividends and preference for Ping An suggests sector fund fragmentation risks. Nevertheless, fundamentals remain robust: Q1 2026 net profit surged 10.41% year-over-year to HK$11.38 billion, operating revenue up 2.32% year-over-year to HK$78.61 billion, and HSBC Research recently upgraded its target price to HK$44 with a Buy rating maintained. Management's accelerated equity allocation since year-start reflects sustained confidence. Valuation-wise, the stock trades 26.45% below its 52-week high of HK$40.46, with PE of 4.69 and PB of 0.79 appearing undervalued; however, year-to-date losses of 17.79% and a position below the 60-day moving average at 30.89 suggest near-term technical headwinds persist.